Sequana Medical announces initial positive data from MOJAVE,

Sequana Medical announces initial positive data from MOJAVE, a US Phase 1/2a study of DSR® 2.0 for treatment of heart failure through breaking vicious cycle of cardiorenal syndrome

Sequana Medical announces initial positive data from MOJAVE, a US Phase 1/2a study of DSR® 2.0 for treatment of heart failure through breaking vicious cycle of cardiorenal syndrome

streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

Related Keywords

United States , Belgium , Canada , American , Jeffrey Testani , Company Or Sequanamedical , York Heart Association , Professor At Yale University , Sequana Medical , Euronext Brussels , Associate Professor , Yale University , Heart Failure Scientific Advisor , Chief Medical Officer , Safety Monitoring Board , Seattle Heart Failure , Conference Call , New York Heart Association , North American , Pre Market Approval , Data Safety Monitoring , Glomerular Filtration Rate ,